Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

351 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Real-world evidence of efficacy of pembrolizumab plus chemotherapy and nivolumab plus ipilimumab plus chemotherapy as initial treatment for advanced non-small cell lung cancer.
Kaneko A, Kobayashi N, Miura K, Matsumoto H, Somekawa K, Hirose T, Kajita Y, Tanaka A, Teranishi S, Sairenji Y, Kawashima H, Yumoto K, Tsukahara T, Fukuda N, Nishihira R, Watanabe K, Horita N, Hara Y, Kudo M, Miyazawa N, Kaneko T. Kaneko A, et al. Among authors: kajita y. Thorac Cancer. 2024 May;15(15):1208-1217. doi: 10.1111/1759-7714.15304. Epub 2024 Apr 11. Thorac Cancer. 2024. PMID: 38602166 Free PMC article.
Retrospective analysis of independent predictors of progression-free survival in patients with EGFR mutation-positive advanced non-small cell lung cancer receiving first-line osimertinib.
Teranishi S, Sugimoto C, Nagaoka S, Nagayama H, Segawa W, Miyasaka A, Hiro S, Kajita Y, Maeda C, Kobayashi N, Yamamoto M, Kudo M, Kaneko T. Teranishi S, et al. Among authors: kajita y. Thorac Cancer. 2022 Oct;13(19):2741-2750. doi: 10.1111/1759-7714.14608. Epub 2022 Aug 18. Thorac Cancer. 2022. PMID: 36082812 Free PMC article.
Thymic atypical carcinoid tumors with elevated mitotic counts in a patient with multiple endocrine neoplasia: A case report.
Hiro S, Teranishi S, Sawazumi T, Nagaoka S, Sugimoto C, Nagayama H, Segawa W, Kajita Y, Maeda C, Kubo S, Seki K, Tashiro K, Kobayashi N, Yamamoto M, Kudo M, Kaneko T. Hiro S, et al. Among authors: kajita y. Thorac Cancer. 2023 May;14(14):1311-1315. doi: 10.1111/1759-7714.14863. Epub 2023 Mar 20. Thorac Cancer. 2023. PMID: 36941083 Free PMC article.
Primary tracheal small-cell carcinoma detected 11 months after surgery for pulmonary large-cell neuroendocrine carcinoma: A case report.
Sugimoto C, Teranishi S, Sawazumi T, Nagaoka S, Nagayama H, Segawa W, Hiro S, Kajita Y, Maeda C, Kubo S, Seki K, Tashiro K, Kobayashi N, Yamamoto M, Kudo M, Kaneko T. Sugimoto C, et al. Among authors: kajita y. Thorac Cancer. 2023 May;14(13):1212-1216. doi: 10.1111/1759-7714.14860. Epub 2023 Mar 28. Thorac Cancer. 2023. PMID: 36977572 Free PMC article.
Predictors of lung injury during durvalumab maintenance therapy following concurrent chemoradiotherapy in unresectable locally advanced non-small cell lung carcinoma.
Hirama N, Yamamoto M, Nagaoka S, Segawa W, Sugimoto C, Nagayama H, Hiro S, Kajita Y, Maeda C, Kubo S, Seki K, Nagahara Y, Teranishi S, Tashiro K, Hara Y, Kobayashi N, Watanabe S, Kudo M, Kaneko T. Hirama N, et al. Among authors: kajita y. Thorac Cancer. 2023 Sep;14(25):2601-2607. doi: 10.1111/1759-7714.15042. Epub 2023 Aug 2. Thorac Cancer. 2023. PMID: 37533115 Free PMC article.
Comparison of the slow-pull and aspiration methods of endobronchial ultrasound-guided transbronchial needle aspiration for next-generation sequencing-compatible tissue collection in non-small cell lung cancer.
Kajita Y, Teranishi S, Sawazumi T, Watanabe H, Nagaoka S, Tanaka A, Suzukawa Y, Motobayashi Y, Hirose T, Maeda C, Seki K, Tashiro K, Kobayashi N, Yamamoto M, Kudo M, Inayama Y, Kaneko T. Kajita Y, et al. Cancer Med. 2023 Oct;12(19):19512-19522. doi: 10.1002/cam4.6561. Epub 2023 Sep 21. Cancer Med. 2023. PMID: 37732488 Free PMC article.
Tailoring Therapeutic Strategies in Non-Small-Cell Lung Cancer: The Role of Genetic Mutations and Programmed Death Ligand-1 Expression in Survival Outcomes.
Kobayashi N, Miura K, Kaneko A, Matsumoto H, Somekawa K, Hirose T, Kajita Y, Tanaka A, Teranishi S, Sairenji Y, Kawashima H, Yumoto K, Tsukahara T, Fukuda N, Nishihira R, Kudo M, Miyazawa N, Kaneko T. Kobayashi N, et al. Among authors: kajita y. Cancers (Basel). 2023 Oct 31;15(21):5248. doi: 10.3390/cancers15215248. Cancers (Basel). 2023. PMID: 37958421 Free PMC article.
Total baseline tumor size predicts survival among patients with advanced small-cell lung cancer receiving chemotherapy plus programmed death-ligand 1 inhibitor as first-line therapy: a multicenter retrospective observational study.
Tanaka A, Teranishi S, Kajita Y, Hirose T, Kaneko A, Sairenji Y, Kawashima H, Yumoto K, Tsukahara T, Miura K, Kobayashi N, Yamamoto M, Nishihira R, Kudo M, Miyazawa N, Nishikawa M, Kaneko T. Tanaka A, et al. Among authors: kajita y. Front Oncol. 2024 Nov 4;14:1400277. doi: 10.3389/fonc.2024.1400277. eCollection 2024. Front Oncol. 2024. PMID: 39558947 Free PMC article.
351 results